Sat, May 31, 2025
Fri, May 30, 2025
Thu, May 29, 2025
Wed, May 28, 2025
Tue, May 27, 2025
Mon, May 26, 2025
Sun, May 25, 2025
Sat, May 24, 2025
Fri, May 23, 2025
Thu, May 22, 2025
Wed, May 21, 2025
Tue, May 20, 2025
[ Tue, May 20th ] - 13abc
Moment of Science: Cicadas
Mon, May 19, 2025
Sun, May 18, 2025
Sat, May 17, 2025
Fri, May 16, 2025
Thu, May 15, 2025
Wed, May 14, 2025
Tue, May 13, 2025
[ Tue, May 13th ] - WSAZ
Summer science experiments
Mon, May 12, 2025
Sun, May 11, 2025
Sat, May 10, 2025
Fri, May 9, 2025
Thu, May 8, 2025
Wed, May 7, 2025

Anavex Life Sciences Corp. (AVXL) Q2 2025 Earnings Call Transcript


//science-technology.news-articles.net/content/2 .. -corp-avxl-q2-2025-earnings-call-transcript.html
Published in Science and Technology on Tuesday, May 13th 2025 at 10:22 GMT by   Print publication without navigation

  • Anavex Life Sciences Corp. (NASDAQ:AVXL) Q2 2025 Earnings Conference Call May 13, 2025 8:30 AM ETCompany ParticipantsClint Tomlinson - Investor...

Anavex Life Sciences Corp. (AVXL) held its Q2 2025 earnings call, discussing the progress and updates on their clinical programs. The company highlighted the ongoing Phase 2b/3 ANAVEX®2-73 (blarcamesine) study for Alzheimer's disease, noting that enrollment is on track with top-line data expected in Q4 2025. They also provided updates on the ANAVEX®3-71 (aficamten) program for Rett syndrome, with the Phase 2 study showing positive preliminary results and plans for further expansion. Additionally, Anavex discussed their financial position, reporting a strong cash reserve that supports their ongoing and planned clinical trials. The call emphasized the company's commitment to advancing treatments for neurodegenerative and neurodevelopmental disorders.

Read the Full Seeking Alpha Article at:
[ https://seekingalpha.com/article/4786024-anavex-life-sciences-corp-avxl-q2-2025-earnings-call-transcript ]